Current Report Filing (8-k)
February 04 2019 - 6:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 31, 2019
Cocrystal
Pharma, Inc.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-38418
|
|
35-2528215
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
19805 N. Creek Parkway
Bothell, WA
|
|
98011
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (786) 459-1831
(Former name or former address, if changed since
last report.): N/A
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company [ ]
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d)
On January 31, 2019, the Board of Directors (the “Board”)
of Cocrystal Pharma, Inc. (the “Company”) appointed Mr. Todd Brady as a director, effective February 1, 2019. Mr. Brady
was also appointed as a member of the Audit Committee of the Board. He was designated by Dr. Raymond Schinazi, our principal stockholder,
pursuant to the Stockholder Rights Agreement, dated November 24, 2014.
Todd Brady, 39, has served as the Director of Finance and Investments
at Brace Pharma Capital, Inc. since April 2014. There are no related party transactions between the Company and Mr. Brady reportable
under Item 404(a) of Regulation S-K.
Item 8.01. Other Events.
On December 6, 2018, we notified Emory University
(“Emory”) of the termination of our License Agreement with Emory, dated March 7, 2013 (the “License Agreement”).
The License Agreement covered patents and patent applications for hepatitis C virus (“HCV”) inhibitors, which we no
longer consider essential to our HCV program. As part of our HCV program, we continue to focus our efforts on CC-31244, our HCV
Non-Nucleoside Polymerase Inhibitor, in Phase 2a clinical trial. The Company had the right to terminate the License Agreement
at its sole discretion upon a 90 days’ prior written notice and upon payment of all amounts due Emory under the License
Agreement through the date of termination. As of the date of this Current Report on Form 8-K, no amounts were due under the License
Agreement. The Company is presently evaluating the extent to which the termination of the License Agreement may require
it to impair some of its intangible assets.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Cocrystal Pharma, Inc.
|
|
|
|
Date: February 1, 2019
|
By:
|
/s/ James Martin
|
|
Name:
|
James Martin
|
|
Title:
|
Chief Financial Officer
|
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024